Format

Send to

Choose Destination
Respiration. 2018;96(1):52-65. doi: 10.1159/000487713. Epub 2018 Apr 10.

Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.

Salzer HJF1,2, Schäfer G3,4, Hoenigl M5,6, Günther G1,7, Hoffmann C8,9, Kalsdorf B1,2, Alanio A10,11,12, Lange C1,2,13,14.

Author information

1
Division of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
2
German Center for Infection Research, Clinical Tuberculosis Center, Borstel, Germany.
3
Infectious Diseases Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
4
Section of Rheumatology, 3rd Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
5
Division of Infectious Diseases, University of California at San Diego, San Diego, California, USA.
6
Section of Infectious Diseases and Tropical Medicine and Division of Pulmonology, Medical University of Graz, Graz, Austria.
7
Department of Internal Medicine, School of Medicine, University of Namibia, Windhoek, Namibia.
8
Infektionsmedizinisches Centrum Hamburg (ICH) Study Center, Hamburg, Germany.
9
Department of Medicine II, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
10
Parasitology-Mycology Laboratory, Lariboisière Saint-Louis Fernand Widal Hospitals, Assistance Publique-Hôpitaux de Paris, Paris, France.
11
Paris-Diderot, Sorbonne Paris Cité University, Paris, France.
12
Institut Pasteur, Molecular Mycology Unit, CNRS CMR2000, Paris, France.
13
International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
14
Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Abstract

The substantial decline in the Pneumocystis jirovecii pneumonia (PCP) incidence in HIV-infected patients after the introduction of antiretroviral therapy (ART) in resource-rich settings and the growing number of non-HIV-infected immunocompromised patients at risk leads to considerable epidemiologic changes with clinical, diagnostic, and treatment consequences for physicians. HIV-infected patients usually develop a subacute course of disease, while non-HIV-infected immunocompromised patients are characterized by a rapid disease progression with higher risk of respiratory failure and higher mortality. The main symptoms usually include exertional dyspnea, dry cough, and subfebrile temperature or fever. Lactate dehydrogenase may be elevated. Typical findings on computed tomography scans of the chest are bilateral ground-glass opacities with or without cystic lesions, which are usually associated with the presence of AIDS. Empiric treatment should be initiated as soon as PCP is suspected. Bronchoalveolar lavage has a higher diagnostic yield compared to induced sputum. Immunofluorescence is superior to conventional staining. A combination of different diagnostic tests such as microscopy, polymerase chain reaction, and (1,3)-β-D-glucan is recommended. Trimeth-oprim/sulfamethoxazole for 21 days is the treatment of choice in adults and children. Alternative treatment regimens include dapsone with trimethoprim, clindamycin with primaquine, atovaquone, or pentamidine. Patients with moderate to severe disease should receive adjunctive corticosteroids. In newly diagnosed HIV-infected patients with PCP, ART should be initiated as soon as possible. In non-HIV-infected immunocompromised patients, improvement of the immune status should be discussed (e.g., temporary reduction of immunosuppressive agents). PCP prophylaxis is effective and depends on the immune status of the patient and the underlying immunocompromising disease.

KEYWORDS:

Diagnosis; HIV-infected patients; Non-HIV-infected patients; Pneumocystis jirovecii; Pneumocystis jirovecii pneumonia; Pneumonia; Treatment

PMID:
29635251
DOI:
10.1159/000487713
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center